ERCC1 and BRCA1 mRNA Levels and Chemosensitivity in Cancer
Author Information
Author(s): Wang Lifeng, Wei Jia, Qian Xiaoping, Yin Haitao, Zhao Yang, Yu Lixia, Wang Tingting, Liu Baorui
Primary Institution: Drum Tower Hospital Affiliated to Medical School of Nanjing University
Hypothesis
The study investigates the role of ERCC1 and BRCA1 mRNA expression levels as biomarkers for drug sensitivity in cancer patients with metastases.
Conclusion
ERCC1 and BRCA1 mRNA expression levels are correlated with chemosensitivity to cisplatin and/or docetaxel in malignant effusions of NSCLC and gastric cancer patients.
Supporting Evidence
- ERCC1 expression level is negatively correlated with sensitivity to cisplatin in NSCLC patients.
- BRCA1 expression level is negatively correlated with sensitivity to cisplatin in NSCLC and gastric cancer patients.
- BRCA1 expression level is positively correlated with sensitivity to docetaxel in NSCLC and gastric cancer patients.
- A significant interaction is found between ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin.
Takeaway
This study found that certain genes in cancer cells can help predict how well patients will respond to chemotherapy drugs.
Methodology
Real-time quantitative PCR was used to analyze gene expression in tumor cells from malignant effusions, and sensitivity to cisplatin and docetaxel was tested using ATP-TCA assay.
Limitations
The study's findings may not directly translate to clinical practice due to the in vitro nature of the chemosensitivity tests.
Participant Demographics
{"age":{"median":63,"range":"38–87"},"sex":{"female":21,"male":25},"primary_tumor":{"NSCLC":20,"gastric":21,"gynecological":5}}
Statistical Information
P-Value
{"ERCC1_cisplatin":0.001,"BRCA1_cisplatin_NSCLC":0.014,"BRCA1_cisplatin_gastric":0.002,"BRCA1_docetaxel_NSCLC":0.008,"BRCA1_docetaxel_gastric":0.032,"interaction":0.01}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website